Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949.
Primidone was granted FDA Approval on 8 March 1954.
Primidone is commonly indicated for the management of grand mal, psychomotor, and focal epileptic seizures. In addition, it has also been studied and utilized as an effective management of essential tremor.
Departmet of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia
AP-HP Cochin, Paris, France
Dent Neurologic Institute, Amherst, New York, United States
Bioserve Clinical Research Pvt. Ltd,, HYD, Andhra Pradesh, India
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.